Drug intelligence / Profile preview

PRO CAR-201A

Development stage: Unknown
Lead developer: PromiCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PRO CAR-201A is an autologous, unarmored CAR T cell therapy targeting the Six-transmembrane epithelial antigen of the prostate 1 (STEAP1). Developed by PromiCell and licensed from the Fred Hutchinson Cancer Center, it is designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapy involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) that recognizes STEAP1, a protein highly expressed on the surface of prostate cancer cells, leading to targeted tumor cell lysis. Initial clinical trial readouts for safety and efficacy are anticipated in mid-2025.

Targets

STEAP1 (Six-transmembrane epithelial antigen of prostate 1)

Beyond the preview

Go deeper on PRO CAR-201A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO CAR-201A.

Explore the full profile